Showing 4521-4530 of 5771 results for "".
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- FDA Approves Bausch + Lomb Alaway Preservative Free OTC Dropshttps://modernod.com/news/fda-approves-bausch-lomb-alaway-preservative-free-ophthalmic-solution/2478329/Bausch + Lomb and Eton Pharmaceuticals announced that the FDA has approved Alaway Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp
- Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-selects-0-1-ncx-470-dose-in-adaptive-stage-of-mont-blanc-phase-3-glaucoma-trial/2478316/Nicox SA announced the selection of the 0.1% dose of NCX 470 for phase 3 following the completion of the adaptive portion of the Mont Blanc phase 3 clinical trial. As is customary for adaptive design trials, in order to maintain the integrity of the trial, no data from the adaptive portion of the
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Fauci Offers Defense of Why Americans Can Trust the Approval Process for a Potential COVID-19 Vaccinehttps://modernod.com/news/fauci-offers-defense-of-why-americans-can-trust-the-approval-process-for-a-potential-covid-19-vaccine/2478314/A potential COVID-19 vaccine is likely to approved in November or December, but the announcement of any such vaccine will not be based in any way on a political timeline, infectious disease expert Anthony Fauci, MD, said Tuesday evening during The Atlantic Festival, according to a FierceHealthcar
- Lumenis Unveils Its First US Tour With Launch Of Mobile Outdoor Tradeshow Boothhttps://modernod.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/Lumenis has announced its first mobile tour (LuMobile), September 28 through April 2021. The company will bring its flagship devices to practitioners in a safe environment aboard the new LuMobile outdoor tradeshow exhibit. The 20-city mo
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- Rayner to Launch RayOne EMV Enhanced Monofocal IOLhttps://modernod.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/Rayner has announced the upcoming European launch of RayOne EMV, a new fully preloaded non-diffractive IOL designed to enhance patient outcomes achieved with monovision. Developed in collaboration with Professor Graham Barrett, president of the Australasian Society of Cata